Phil Deschamps | Chief Executive Officer |
Marcos Rodrigues | Physical Therapist-Neurotherapy Montreal Clinic |
Joyce LaViscount | Chief Financial Officer and Chief Operating Officer |
Ameer Burshaw | Oppenheimer |
Jeff Porter | Porter Capital |
Sebastian van Berkom | Van Berkom and Associates |
Good afternoon, ladies and gentlemen, and welcome to the Second Quarter of Fiscal Year 2019 Earnings Conference Call for Helius Medical Technologies. [Operator Instructions] Please note, that this conference call is being recorded and that the recording will be available on the company's website for replay shortly.
Before we begin, I would like to remind everyone that our remarks and responses to your questions today may contain forward-looking statements that are based on current expectations of management, including statements regarding the potential FDA marketing authorization of the PoNS device, the future commercialization of the PoNS treatment, expected future clinical and regulatory timelines and projected financial results.
These forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from those indicated, including those identified in the risk factor section of our most recent annual report on Form 10-K filed with the SEC on March 14, 2019, as well as those in the Form 10-Q for the second quarter ended June 30, 2019, which was filed with the SEC this afternoon.
Such factors may be updated from time to time in our filings with the SEC, which are available on our website.